GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuformix PLC (LSE:NFX) » Definitions » EV-to-EBIT

Nuformix (LSE:NFX) EV-to-EBIT : -1.72 (As of May. 23, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Nuformix EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nuformix's Enterprise Value is £1.31 Mil. Nuformix's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was £-0.76 Mil. Therefore, Nuformix's EV-to-EBIT for today is -1.72.

The historical rank and industry rank for Nuformix's EV-to-EBIT or its related term are showing as below:

LSE:NFX's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 10.345
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Nuformix's Enterprise Value for the quarter that ended in Sep. 2022 was £2.16 Mil. Nuformix's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was £-0.76 Mil. Nuformix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -35.22%.


Nuformix EV-to-EBIT Historical Data

The historical data trend for Nuformix's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuformix EV-to-EBIT Chart

Nuformix Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
EV-to-EBIT
Get a 7-Day Free Trial -4.44 -6.23 -20.91 -8.48 -4.36

Nuformix Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.48 - -4.36 - -

Competitive Comparison of Nuformix's EV-to-EBIT

For the Biotechnology subindustry, Nuformix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuformix's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuformix's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nuformix's EV-to-EBIT falls into.



Nuformix EV-to-EBIT Calculation

Nuformix's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1.313/-0.762
=-1.72

Nuformix's current Enterprise Value is £1.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nuformix's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was £-0.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nuformix  (LSE:NFX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Nuformix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2022 ) =EBIT / Enterprise Value (Q: Sep. 2022 )
=-0.762/2.1635124
=-35.22 %

Nuformix's Enterprise Value for the quarter that ended in Sep. 2022 was £2.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nuformix's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was £-0.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nuformix EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Nuformix's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuformix (LSE:NFX) Business Description

Traded in Other Exchanges
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.